OCEA (oceanbiomedical.com) Market Value to Book Value Ratio

Official company branding of Ocean Biomedical Inc (OCEA)

The price-to-book value ratio dynamics reflect the market valuation of Ocean Biomedical, Inc. (OCEA) assets, where the metric stands at 0.00. The business relies on outsourcing, delegating production and testing to external partners. Growth is driven by developments in cancer immunotherapy and malaria vaccination. Prospects depend on the conclusion of licensing deals, although oncology speculations are already partially priced in.

OCEA Ocean Biomedical Corp: Market Value to Book Value in the range 04/28/2023 - 05/24/2025
Original product of Ocean Bio

Ocean Biomedical, Inc. (OCEA) maintains stability through the diversification of its raw material supply chains for vaccines. The current ratio of the company's value to its book capitalization compares the market price of shares with the volume of net assets. This coefficient reflects the market consensus regarding the real-time valuation of the business. An increase in this indicator signals inflated investor expectations, while a decrease indicates an undervaluation of the holding's fundamental value.

Main competitors

ARGX: Market Capitalization to Book Value Ratio|BNTX (biontech.de) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio abivax.com ABVX|Market Capitalization to Net Assets ADMA Biologics Inc|Protagonist Therapeutics Inc (PTGX) - Market Capitalization to Book Value Ratio|Market Value to Book Value Immunovant Therapeutics (IMVT)|Market Capitalization to Book Value Ratio KNSA (Kiniksa Pharmaceuticals)|grifols.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Adaptive Biotechnologies Corporation (ADPT)|CLDX: Market Value to Book Value|AUPH (Aurinia Pharma) - Market Value to Book Value Ratio|BioCryst Corp (BCRX) - Market Cap to Net Assets Ratio|VERA (Vera Therapeutics, Inc.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio dianthustx.com (DNTH)|Pharvaris (PHVS) - Market Cap to Net Assets Ratio|Market Value to Book Value AbCellera Biologics (ABCL)|Market Capitalization to Book Value Ratio TRML|Precigen Corp - Market Capitalization to Book Value|PHAR: Market Value to Book Value Ratio|NKTR: Market Cap to Net Assets Ratio|UPB (Upstream Bio) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Zenas Bio|IMNM (Immunome Corp) - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio GOSS|Market Value to Book Value Ratio KalVista Pharmaceuticals KALV|Capitalization to Book Value Ratio septerna.com (SEPN)|PVLA: Market Capitalization to Book Value Ratio|Savara Inc - Market-to-Book Ratio|RIGL (Rigel Pharmaceuticals Inc) - Market Value to Book Value Ratio|ANAB - Market-to-Book Ratio|ATXS (Astria Therapeutics) - Market Capitalization to Book Value Ratio|engene.com (ENGN) - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio RAPT (RAPT Therapeutics)|Market-to-Book Ratio Aerovate|Market Capitalization to Book Value Ratio ACRS|Market Capitalization to Book Value Ratio KYTX (Kyverna Therapeutics, Inc)|TLSA - Market Value to Book Value Ratio|CABA - Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio Ventyx Biosciences, Inc. (VTYX)|THTX - Market Value to Book Value|Avalo Therapeutics Inc. (AVTX) - Market Capitalization to Book Value Ratio|Eledon Pharmaceuticals, Inc (ELDN) - Market Value to Book Value Ratio|AGEN: Market Capitalization to Book Value Ratio|Market Capitalization to Book Value CLYM|Zura Bio - Market Value to Book Value Ratio|Market-to-Book Ratio ATYR (aTyr Pharma Inc)|Adagene Inc. - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio ImageneBio IMA|STTK (Shattuck Therapeutics) - Market Capitalization to Book Value Ratio|EQ - Market-to-Book Ratio|Market Capitalization to Book Value Ratio connectbiopharm.com|Immunic (IMUX) - Capitalization to Book Value Ratio|ATRA: Market Capitalization to Book Value Ratio|Market Capitalization to Book Value InflaRx GmbH|Market Capitalization to Book Value Ratio XFOR (X4 Pharmaceuticals)|Market Cap to Net Assets Ratio adicetbio.com (ACET)|Market Capitalization to Book Value Ratio CELU (Celularity)|INmune Bio Inc - Market Capitalization to Book Value Ratio|BRNS - Market Value to Book Value Ratio|Kezar Life Sciences Inc (KZR) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio SAB Biotherapeutics SABS|akaritx.com (AKTX) - Market Value to Book Value|ENLV: Market Capitalization to Book Value Ratio|Market Capitalization to Book Value QTTB|Market Value to Book Value Ratio GeoVax Labs Inc GOVX|Capitalization to Book Value Ratio Edesa Biotech Corp (EDSA)|iBio, Inc. - Market Capitalization to Book Value Ratio|CARM - Market Cap to Net Assets Ratio|Market Cap to Net Assets Ratio XTLB (XTL Biopharmaceuticals Ltd.)|BOLT: Market Capitalization to Book Value|Market Value to Book Value Ratio HCWB|Aptevo Therapeutics Inc. (APVO) - Market-to-Book Ratio|Market Capitalization to Book Value Ratio AIM|Market Cap to Net Assets Ratio Aditxt Corp|GRI Bio - Market Capitalization to Book Value Ratio|Market-to-Book Ratio XORTX Therapeutics Inc (XRTX)|Market Capitalization to Book Value Ratio HIND (ReShape Lifesciences)|Revelation Biosciences Corp - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Indaptus Therapeutics|SCNI - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio calcimedica.com CALI|Affimed N.V. (AFMD) - Market Value to Book Value|ALLK (Allakos Inc) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio HOOK|IGM Biosciences, Inc. (IGMS) - Market Value to Book Value Ratio|Market Value to Book Value ITOS (iteostherapeutics.com)|TC BioPharm - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Third Harmonic Bio Inc. THRD